explore -WSS

explore

author：entertainment 2025-09-30 15:17:02 - browse：47796

A pharmacist hands a box of Wegovy — first opinion coverage from STAT — Bloomberg photo by George Frey

LONDON — Novo Nordisk said Wednesday that it had started to increase the availability of its blockbuster obesity drug Wegovy for new patients in the United States, after massive demand and a supply crunch had led it to limit doses last May.

The announcement that Novo was making more of its lower-dose starter product available as of this month came as the company reported its 2023 earnings, with sales up by 36% and operating profit up 44% at constant exchange rates, driven by enormous sales of Wegovy and Ozempic, the company’s sister drug for diabetes. The company also projected double-digit growth in sales and operating profit for 2024.

“I am pleased to state that we are now enabling more new U.S. patients to initiate treatment by more than doubling the amount of lower-dose strength Wegovy compared to previous months,” Novo CEO Lars Fruergaard Jørgensen said on a call with reporters.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： Study: Black kids more likely to die after surgery than white kids

knowledge

entertainment

WSS

Hundreds died while taking an arthritis drug, but nobody alerted patients

Baby aspirin cuts fat buildup in liver disease patients, in small study

Bird flu in dairy cattle: New measures to control spread to humans

UnitedHealth increases loan offers after Change Healthcare outage

U.K. researchers warn about biases in medical devices, algorithms

Gut bacteria may contribute to kidney autoimmunity, study finds

knowledge

explore

leisure time

Affirmative action in medical school literally saved lives

Baby aspirin cuts fat buildup in liver disease patients, in small study

Anesthesiologist group: stop taking Ozempic before surgery

Gut bacteria may contribute to kidney autoimmunity, study finds

Moonlake's readout produced a cash windfall. Risks remain

Trial using CRISPR to edit HIV out of cells disappoints

Hollywood unions extend contract negotiations for actors

Neuroscience’s long legacy of racism

Novavax promises a turnaround & Lilly roils the obesity market

Physicians and social media: If you see something, say something?

focus

Stop the failed accountable care organization experiment

Argenx readies a blockbuster opportunity with drug for autoimmune disease

Alzheimer's risk factor APOE4 may be a distinct form of the disease

Depression: FDA OKs Otsuka Pharmaceuticals digital therapeutic

Orchard's therapy for neuron disease in children wins FDA approval

Young boy dies in trial for Pfizer Duchenne gene therapy

knowledge

knowledge

entertainment

hotspot